| Full Name | Bo Chen |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 619 19th St S, Birmingham, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427402007 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 38844 (Alabama) | Primary |
| Entity Name | University Medical Service Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992742324 PECOS PAC ID: 6800790221 Enrollment ID: O20031126000130 |
News Archive
While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.
Solid-state nuclear magnetic resonance, or SSNMR, is a valuable tool to image and analyze the chemical makeup of proteins and other biomolecules.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.
› Verified 2 days ago
| Entity Name | Ruffolo Hooper & Associates Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790732360 PECOS PAC ID: 1355324658 Enrollment ID: O20040609000084 |
News Archive
While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.
Solid-state nuclear magnetic resonance, or SSNMR, is a valuable tool to image and analyze the chemical makeup of proteins and other biomolecules.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bo Chen, 619 19th St S, Birmingham, AL 35233-1900 Ph: () - | Bo Chen, 619 19th St S, Birmingham, AL 35233-1900 Ph: (205) 934-4011 |
News Archive
While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.
Solid-state nuclear magnetic resonance, or SSNMR, is a valuable tool to image and analyze the chemical makeup of proteins and other biomolecules.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.
› Verified 2 days ago
Dr. Kyle Charles Mills, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2800 Fax: 205-949-2801 | |
Leona Council, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5038 | |
Dr. Alexander Wong, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2806 Fax: 205-949-2875 | |
Dr. David Ullman, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 625 19th St S, Birmingham, AL 35233 Phone: 205-934-4977 | |
Dr. Jonathan G Phillips, MD Pathology Medicare: Medicare Enrolled Practice Location: 924 Montclair Rd, Ste 200, Birmingham, AL 35213 Phone: 205-591-7999 Fax: 205-591-5051 | |
Thomas S Winokur, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Isam Eltoum, Pathology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 |